- Home
- NKTX vs GNLX Comparison
NKTX vs GNLX Comparison
Compare NKTX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- GNLX
- Stock Information
- Founded
- NKTX 2015
- GNLX 2001
- Country
- NKTX United States
- GNLX United States
- Employees
- NKTX N/A
- GNLX N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- GNLX Health Care
- Exchange
- NKTX Nasdaq
- GNLX Nasdaq
- Market Cap
- NKTX 123.5M
- GNLX 129.9M
- IPO Year
- NKTX 2020
- GNLX 2023
- Fundamental
- Price
- NKTX $2.12
- GNLX $3.51
- Analyst Decision
- NKTX Strong Buy
- GNLX Strong Buy
- Analyst Count
- NKTX 6
- GNLX 5
- Target Price
- NKTX $14.40
- GNLX $16.20
- AVG Volume (30 Days)
- NKTX 578.6K
- GNLX 157.6K
- Earning Date
- NKTX 08-12-2025
- GNLX 08-13-2025
- Dividend Yield
- NKTX N/A
- GNLX N/A
- EPS Growth
- NKTX N/A
- GNLX N/A
- EPS
- NKTX N/A
- GNLX N/A
- Revenue
- NKTX N/A
- GNLX N/A
- Revenue This Year
- NKTX N/A
- GNLX N/A
- Revenue Next Year
- NKTX N/A
- GNLX N/A
- P/E Ratio
- NKTX N/A
- GNLX N/A
- Revenue Growth
- NKTX N/A
- GNLX N/A
- 52 Week Low
- NKTX $1.31
- GNLX $1.60
- 52 Week High
- NKTX $6.66
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- NKTX 57.92
- GNLX 56.95
- Support Level
- NKTX $1.74
- GNLX $3.30
- Resistance Level
- NKTX $2.32
- GNLX $3.70
- Average True Range (ATR)
- NKTX 0.15
- GNLX 0.27
- MACD
- NKTX 0.02
- GNLX -0.01
- Stochastic Oscillator
- NKTX 62.96
- GNLX 72.86
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.